L
L

Lonza

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Lonza Group AG Reconfirms 2023 Outlook

BRIEF-Lonza Group AG Reconfirms 2023 Outlook Sept 21 (Reuters) - Lonza Group AG LONN.S : RECONFIRMING ITS OUTLOOK 2023 DURING COMPANY'S HALF-YEAR RESULTS PRESENTATION IN JULY 2023, OUTLOOK WAS SET AT MID-TO-HIGH SINGLE-DIGIT CER SALES GROWTH AND 28 TO 29% CORE EBITDA MARGIN Source text for Eikon: [ID:] Further company coverage: LONN.S Reporting by
L

Brooks MacDonald Group, TUI, Weir Group

EUROPE RESEARCH ROUNDUP- Brooks MacDonald Group, TUI, Weir Group Sept 21 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Brooks MacDonald Group, TUI and Weir Group, on Thursday. HIGHLIGHTS * Brooks MacDonald Group Plc BRK.L : RBC cuts target price to 1,900p from 2,100p * Duell Oyj DUELL.HE : Evli Research cuts to hold from buy * Merck KGaA MRCG.DE : Citigroup raises to buy from neutral * TUI AG TUI1n.DE : Jefferies raises to hold f
A
A
A
A
A
B
B
C
D
E
G
L
L
N
O
O
P
R
R
S
T
T
V
V
W
A
A
E
R

Lonza Confirms Details Of Capital Markets Day And Reconfirms Outlook 2023

BRIEF-Lonza Confirms Details Of Capital Markets Day And Reconfirms Outlook 2023 Sept 21 (Reuters) - LONZA GROUP AG LONN.S : LONZA CONFIRMS DETAILS OF CAPITAL MARKETS DAY AND RECONFIRMS OUTLOOK 2023 Source text for Eikon: ID:nEQ6lhGGta Further company coverage: LONN.S (Gdansk Newsroom)
L

Moderna to cut mRNA drug substance production at Lonza facility

UPDATE 2-Moderna to cut mRNA drug substance production at Lonza facility Adds details on production and demand for COVID shots throughout Sept 19 (Reuters) - Moderna MRNA.O said on Tuesday it will cut production of mRNA drug substance for its COVID-19 vaccine at Lonza's LONN.S facility in Switzerland this quarter as part of a plan to align manufacturing of the shots with lower post-pandemic demand.
L
P
S
T

Moderna to ramp down mRNA drug substance production at Lonza facility

CORRECTED-Moderna to ramp down mRNA drug substance production at Lonza facility Corrects headline and story to say the facility belongs to Lonza, not Moderna Sept 19 (Reuters) - Moderna MRNA.O said on Tuesday it will cut production of mRNA drug substance for its COVID-19 vaccine at Lonza's LONN.S facility in Switzerland this quarter. Reporting by L
L

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

We are using cookies to give you the best experience on our website. Read more or change your cookie settings.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.